ICAM-1 marker and its applications

ICAM-1 is used to regulate adipose stem cell differentiation, addressing the lack of clear markers for adipocyte differentiation and providing tools for adipocyte preparation and obesity diagnosis, with a negative regulatory effect on adipogenic differentiation.

JP7596150B2Active Publication Date: 2024-12-09SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2020562822
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-01-29
Filing Date
2019-01-29
Publication Date
2024-12-09
Estimated Expiration
2039-01-29

AI Technical Summary

Technical Problem

The definition of adipose stem cells and the regulatory mechanisms of their adipogenic differentiation at the cellular and molecular level during obesity are unclear, and existing markers do not clearly distinguish specific types of adipocyte differentiation.

Method used

The use of ICAM-1 inhibitors or promoters to regulate adipose stem cell differentiation, including ICAM-1 positive adipose stromal cells, and the application of ICAM-1 inhibitors to inhibit or promoters to promote adipocyte differentiation, utilizing RNA interference methods and specific antibodies to modulate ICAM-1 expression.

Benefits of technology

ICAM-1 regulates adipose stem cell differentiation, providing tools for adipocyte preparation in vitro and adipose tissue remodeling, and aids in diagnosing obesity risk through ICAM-1 detection, demonstrating a negative regulatory effect on adipogenic differentiation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007596150000003
    Figure 0007596150000003
  • Figure 0007596150000004
    Figure 0007596150000004
  • Figure 0007596150000005
    Figure 0007596150000005
Patent Text Reader

Abstract

The present invention provides the use of ICAM-1 and its regulators in promoting or inhibiting the differentiation of adipose stem cells into adipocytes, as well as the use of ICAM-1 or its detection reagents in (a) detecting adipose stem cells and / or (b) determining a subject's risk of developing obesity, and corresponding diagnostic kits and methods. The present invention further provides a method for non-therapeutic in vitro preparation of adipocytes.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of biotechnology, and more specifically to ICAM-1 and its application in the recognition of adipose stem cells and the regulation of adipocyte differentiation. [Background technology]

[0002] The development of obesity is reflected by an increase in adipose tissue, which includes two actions: adipocyte hypertrophy--the intake and accumulation of excess lipids, and adipocyte hyperplasia. Because mature adipocytes have no mitotic ability, adipocyte hyperplasia is caused by the differentiation of adipose precursor cells into new adipocytes. Adult adipose tissue is renewed at a rate of 10% per year, and in obese people, the rate of adipocyte removal is the same as in normal people, but the rate of neogenesis and replenishment is significantly higher than in normal people, causing adipocyte hyperplasia. In rodents, it is generally believed that inducing obesity with a high-fat diet first increases the size of adipocytes, and the number of adipocytes gradually increases as the time of high-fat diet increases. Through genetically modified mice that can mark neoadipocytes, it has been found that adipogenic differentiation is not obvious in the early stages of obesity, but in the later stages, there are a large number of adipocytes that differentiate into neoadipocytes, especially in visceral adipose tissue. Thus, obesity involves the adipogenic differentiation of adipose stem cells and is an important cause of obesity in humans and rodents. However, the definition of these adipose stem cells and the cellular and molecular mechanisms regulating their in vivo adipogenic differentiation, especially during the obese period, remain unclear.

[0003] Although the in vitro differentiation process of adipocytes and its molecular mechanism have established a complete differentiation system in vitro, it is urgent to study how to regulate adipocyte differentiation in vivo. Many scholars have previously established that Sca-1, CD34, CD29, CD24, PDGFR-β and PDGFR-α can mark adipocyte precursor cells, but these markers have not clearly defined the specific type of adipocyte differentiation.

[0004] Therefore, there is an urgent need in the art to develop new molecules that are able to recognize adipose stem cells and mark adipocyte differentiation. Summary of the Invention [Problem to be solved by the invention]

[0005] The object of the present invention is to provide ICAM-1 and its application in the recognition of adipose stem cells and regulation of adipocyte differentiation. [Means for solving the problem]

[0006] In a first aspect, the present invention provides the use of an ICAM-1 inhibitor for preparing a formulation or composition that promotes differentiation of adipose stem cells into adipocytes. In another preferred example, the adipose stem cells are ICAM-1-positive adipose stromal cells. In another preferred embodiment, the adipose stem cells express CD45 - CD31 - Sca-1 + PDGFR-α + ICAM-1 + It is a cell. In another preferred embodiment, the adipose stem cells express CD45 - CD31 - ICAM-1 + It is a cell. In another preferred embodiment, said adipose stem cells express regulatory genes for adipogenic differentiation. In another preferred embodiment, the adipogenic differentiation regulatory gene is selected from Pparg, Cebpa, Cebpb, Cebpg, Gata2, Gata3, Irs1, Pparg, Cebpa, and Fabp4, or a combination thereof. In another preferred embodiment, said adipose stem cells express characteristic molecules selected from Sca-1, CD34, CD29, CD24, Pdgfr-β, Zfp423, or a combination thereof.

[0007] In another preferred embodiment, the formulation or composition is further used to remodel adipose tissue. In another preferred embodiment, the ICAM-1 inhibitor specifically inhibits the expression or activity of ICAM-1. In another preferred embodiment, the ICAM-1 inhibitor comprises a MicroRNA, an siRNA, an shRNA, or a combination thereof. In another preferred embodiment, the ICAM-1 inhibitor comprises an antibody. In another preferred embodiment, the ICAM-1 is derived from a human or non-human mammal. In another preferred embodiment, the composition is a pharmaceutical composition. In another preferred example, the pharmaceutical composition comprises (a) an ICAM-1 inhibitor, and (b) a pharma- ceutically acceptable carrier. In another preferred embodiment, the pharmaceutical composition is in the form of an oral dosage form, an injection, or an external pharmaceutical dosage form.

[0008] In a second aspect of the present invention, there is provided the use of ICAM-1 or a promoter thereof for preparing a formulation or composition for inhibiting differentiation of adipose stem cells into adipocytes. In another preferred embodiment, the preparation or composition is used to maintain the undifferentiated state of adipose stem cells. In another preferred embodiment, the ICAM-1 promoter specifically promotes the expression or activity of ICAM-1.

[0009] In a third aspect of the present invention, (a) providing ICAM-1 positive adipose stromal cells; (b) culturing the adipose stromal cells under conditions suitable for adipocyte differentiation to obtain a cell population comprising differentiated adipocytes; (c) isolating adipocytes from said cell population; The present invention provides a method for non-therapeutic preparation of adipocytes in vitro, comprising: In another preferred embodiment, the adipose stromal cells are - CD31 - Sca-1+ PDGFR-α + ICAM-1 + It is a cell. In another preferred embodiment, the adipose stromal cells are - CD31 - ICAM-1 + It is a cell. In another preferred example, the ICAM-1-positive adipose stromal cells are adipose stem cells.

[0010] In another preferred example, in steps (b) and (c), the expression level of ICAM-1 is detected to determine the degree of differentiation of adipose stromal cells into adipocytes in the cell population. In another preferred embodiment, the expression level of ICAM-1 in adipose stromal cells decreases as the degree of adipocyte differentiation of said adipose stromal cells increases. In another preferred example, in step (b), the expression of ICAM-1 in the adipose stromal cells is inhibited to promote differentiation of the adipose stromal cells into adipocytes. In another preferred example, in step (b), the ICAM-1 expression level of the adipose stromal cells gradually decreases as the culture proceeds. In another preferred embodiment, in step (b), if the cell population does not essentially express ICAM-1, adipocytes are separated from the cell population. In another preferred example, the term "basically not expressed" means that the ratio N1 / N2, where N1 is the number of cells expressing ICAM-1 and N2 is the total number of cells in the cell population, is 5% or less, preferably 1% or less.

[0011] A fourth aspect of the present invention provides a method for non-therapeutic in vitro inhibition of differentiation of adipose stem cells into adipocytes, comprising maintaining an expression level of ICAM-1 in the adipose stem cells. In another preferred example, maintaining the ICAM-1 expression level comprises adding ICAM-1 or a promoter thereof to a culture system of adipose stem cells.

[0012] In a fifth aspect of the present invention, there is provided the use of ICAM-1 or a detection reagent thereof for use in preparing a detection kit for (a) detecting adipose stem cells and / or (b) determining the risk of a subject to develop obesity. In another preferred embodiment, the kit further comprises FABP4 or a detection reagent thereof. In another preferred embodiment, the adipose stem cells have adipogenic differentiation potential. In another preferred embodiment, the adipose stem cells are capable of differentiating into adipocytes, resulting in an increase in the number of adipocytes.

[0013] In another preferred embodiment, the detection of adipose stem cells is (i) whether the detection sample contains adipose stem cells; and / or (ii) Detection of the number of adipose stem cells contained in a detection sample. In another preferred embodiment, the sample is a tissue sample, preferably the tissue sample comprises adipose tissue, more preferably the tissue is perivascular adipose tissue. In another preferred embodiment, the kit comprises: + The proportion of cells or the expression level of ICAM-1 of cells in the detection sample is detected to detect adipose stem cells. In another preferred embodiment, the assessment includes an auxiliary assessment and / or a pre-treatment assessment.

[0014] In another preferred embodiment, the determination is made by determining whether or not ICAM-1 + Compare cell ratio A1 with the corresponding ICAM-1 + When A1 is significantly higher than A0 as compared to the cell ratio A0, it illustrates that the subject is at high risk of developing obesity. In another preferred embodiment, the determination is performed by determining whether FABP4 + Cell ratio B1 is compared with FABP4 in the normal population. + Compared to the cell ratio B0, if B1 is significantly lower than B0, it explains that the subject is at high risk of developing obesity. In another preferred example, the term "significantly higher" refers to A1 / A0≧1.25, preferably A1 / A0≧1.5, and more preferably A1 / A0≧2.0. In another preferred example, the term "significantly lower" refers to B0 / B1≧1.25, preferably B0 / B1≧1.5, and more preferably B0 / B1≧2.0. In another preferred embodiment, the number of said normal population is at least 100 individuals, preferably at least 300 individuals, more preferably at least 500 individuals, and most preferably at least 1000 individuals.

[0015] In another preferred embodiment, the detection reagent comprises a protein chip, a nucleic acid chip, or a combination thereof. In another preferred embodiment, the detection reagent comprises an ICAM-1 specific antibody. In another preferred embodiment, the ICAM-1 specific antibody is coupled to or carries a detectable marker. In another preferred embodiment, the detectable marker is selected from a chromophore, a chemiluminescent group, a fluorophore, an isotope or an enzyme. In another preferred embodiment, the ICAM-1 specific antibody is a monoclonal or polyclonal antibody.

[0016] In a sixth aspect of the present invention, a diagnostic kit is provided comprising a container containing ICAM-1 or a detection reagent thereof, and a label or instructions clearly indicating that the kit is used for (a) detecting adipose stem cells and / or (b) determining the risk of a subject developing obesity. In another preferred embodiment, the kit further comprises FABP4 or a detection reagent thereof. In another preferred embodiment, the ICAM-1 and FABP are used as standards. In another preferred embodiment, the kit further comprises a sample pretreatment reagent and instructions for detection. In another preferred embodiment, the instructions describe how to detect and interpret the A1 value. In another preferred embodiment, the kit further comprises an ICAM-1 gene sequence and a protein standard.

[0017] In a seventh aspect of the present invention, (a) providing a sample of subjects; A1 is ICAM-1 of the above sample + (b) measuring the proportion of cells; (b) ICAM-1 in normal population samples + (c) comparing the proportion of cells A0 and explaining that if A1 is significantly higher than A0, the subject is at high risk of developing obesity; The present invention provides a method for determining a subject's risk of developing obesity, comprising: In another preferred embodiment, the method further comprises: + The cell ratio B1 was measured, and B1 was compared with the normal population of FABP4 + The method further includes comparing the cell ratio B0 to the cell ratio B1 and describing the subject as being at increased risk for developing obesity if B1 is significantly lower than B0. In another preferred embodiment, the subject is a human or non-human mammal. In another preferred embodiment, the test sample is a tissue sample, preferably an adipose tissue sample.

[0018] In an eighth aspect of the present invention, there is provided a use of stromal cells, said stromal cells being isolated from adipose tissue and being ICAM-1 positive stromal cells, wherein said stromal cells are used to prepare a cell preparation for remodeling adipose tissue. Preferably, said adipose tissue remodelling includes remodelling of facial, buttocks and breast adipose tissue. In another preferred embodiment, said remodeling comprises adipose tissue remodeling in cosmetic applications and adipose tissue remodeling in wound repair. In another preferred embodiment, the remodeling includes adipose tissue filling. In another preferred embodiment, the cosmetic treatment includes cosmetic treatment of the face, waist, legs, chest, hands, and neck. In another preferred embodiment, said remodeling further comprises the filling of adipose tissue in cosmetic, body and orthopedic applications. In another preferred embodiment, the cosmetic effect includes the filling of adipose tissue and the overall cosmetic, body and shaping effect that can be achieved by the filling of adipose tissue. In another preferred embodiment, the formulation further comprises an ICAM-1 inhibitor. Effect of the Invention

[0019] It should be understood that within the scope of the present invention, the above technical features of the present invention and the technical features specifically described below (e.g., in the Examples) can be combined with each other to form new or preferred technical solutions, which will not be repeated here due to space limitations. [Brief description of the drawings]

[0020] [Figure 1] We show that ICAM-1+ adipose stromal cells have the potential to differentiate adipose stem cells. Specifically, flow cytometry is used to sort CD31-CD45- adipose stromal cells of visceral adipose tissue for single cell analysis. Figure 1A shows the analysis of Sca-1 and PDGFR-α expression in CD31-CD45- adipose stromal cells of visceral adipose tissue using flow cytometry technology. Figure 1B shows the expression level of ICAM-1 in CD31-CD45-Sca-1+PDGFR-α+ cell populations of visceral adipose tissue (epididymal fat) and subcutaneous adipose tissue (inguinal fat) using flow cytometry. Figure 1C shows that ICAM-1+ and ICAM-1- cells in the CD31-CD45-Sca-1+PDGFR-α+ cell population were sorted and the expression levels of adipogenic differentiation and adipose stem cell-related genes were detected by real-time PCR. Figure 1D shows that ICAM-1- cells were isolated from the CD31-CD45-Sca-1+PDGFR-α+ cell population in wild-type mouse adipose tissue and ICAM-1+ cells were isolated from the CD31-CD45-Sca-1+PDGFR-α+ cell population in GFP mouse adipose tissue, and then co-cultured to observe the spontaneous adipogenic differentiation of the cells.

[0021] [Figure 2A-D] In vivo adipogenic differentiation of ICAM-1+ adipose stem cells. Figure 2A shows that mTmG mice were crossed with Icam1-CreERT2 knock-in mice, and the recombinase was activated with tamoxifen to construct ICAM-1 adipose stem cell tracer mice. Figure 2B shows the observation of the situation of adipocytes generated by ICAM-1+ adipose stem cells during the development process of newborn mouse adipose tissue by the overall fluorescent staining technique of adipose tissue. Figure 2C shows the observation of the situation of adipocytes generated by ICAM-1+ adipose stem cells during the process of inducing obesity by high-fat diet by the overall fluorescent staining technique of adipose tissue. [Figure 2D] Figure 2D shows the results of isolating CD45-CD31-ICAM-1+ cells and CD45-CD31-ICAM-1- cells in adipose tissue after hybridization of Icam1-CreERT2 knock-in mice and tracer-reporter mice mTmG. The above cells were then isolated from Matrigel (basement membrane matrix), mixed and transplanted into the subcutaneous tissue of mice, and treated with tamoxifen to observe fat differentiation.

[0022] [Diagram 3]Evolutionary characteristics of ICAM-1+ adipose stem cells under obese conditions. Figure 3A shows that adipose stem cells in adipogenic differentiation of Fabp4-Cre construct, mTmG mice were studied. Figure 3B shows the expression level of ICAM-1 in preadipocytes in adipogenic differentiation state of adipose tissue using flow cytometry. Figure 3C shows the expression level of FABP4 (EGFP marker) of ICAM-1+ adipose stem cells in visceral adipose tissue and subcutaneous adipose tissue under obesity induced by normal diet and high fat diet using flow cytometry. Figure 3D and Figure 3E are repeated statistical analysis of the experiment shown in Figure 3. Figure 3F shows the transcriptome analysis and correlation analysis of adipocytes (Adi), ICAM-1+EGFP+ (I+G+), ICAM-1+EGFP- (I+G-) and ICAM-1- (I-) cells sorted using flow cytometry. Figure 3G shows transcriptome analysis of differentially expressed genes in mature adipocytes, I+G+ cells, I+G- cells and I- cells, mainly related to PPAR signaling, lipogenesis and absorption, acid biosynthesis, and fatty acid elongation.

[0023] [Figure 4]This shows that ICAM-1 negatively regulates the directed differentiation of adipose stem cells. Figure 4A shows the weight changes of wild-type (WT) mice and ICAM-1- / - mice under normal and high-fat diet conditions. Figure 4B shows the weight changes of adipose tissue of wild-type (WT) mice and ICAM-1- / - mice under normal and high-fat diet conditions. Figure 4C shows the results of fluorescent staining analysis of the size of adipocytes in adipose tissue. Figure 4D shows the statistical results of the size of adipocytes in adipose tissue analyzed by fluorescent staining. Figures 4E to 4H show that WT mouse bone marrow was transplanted into WT mice and ICAM-1- / - mice after irradiation to reconstruct bone marrow and feed them a high-fat diet, and the mouse weight changes (Figure 4E) and adipose tissue weight changes (Figure 4F) were observed at different time points, and the size of adipocytes in adipose tissue (Figure 4G) was analyzed by fluorescent staining and statistical analysis was performed (Figure 4H), respectively. Figure 4I shows that ICAM-1- / - mice and ICAM-1+ / + mice were crossed with Fabp4-Cre;mTmG mice, respectively, and the status of adipocytes generated by adipose stem cells under ICAM-1 deletion conditions was analyzed by flow cytometry, and statistical analysis was performed. Figure 4J shows that statistical analysis of flow cytometry analysis as shown in 4I was performed on multiple mice. Figure 4K shows that the content of GFP in adipose tissue stromal cells was analyzed by western blot to reveal the regeneration status of adipocytes.

[0024] [Diagram 5] We show that ICAM-1 negatively regulates adipogenic differentiation of adipose stem cells. Figures 5A-5D show that we isolated adipose stem cells from WT and ICAM-1- / - mice, subjected them to adipogenic differentiation, and detected the expression of adipogenic differentiation-related genes, including Pparg (Figure 5A), Cebpa (Figure 5B), Fabp4 (Figure 5C), and Plin1 (Figure 5D), at different time points, respectively.

[0025] [Figure 6]We show that ICAM-1 negatively regulates the directed differentiation of adipose stem cells through Rho GTPase. Figure 6A shows that the expression levels of Rho-GTP, Rho-GDP and total Rho in adipose stem cells derived from WT and ICAM-1- / - mice were detected using active Rho GTPases pull-down experiments. Figure 6B shows the results of F-actin cytoskeleton staining. Figure 6C shows that DMSO or 10 μM Y-27632 (ROCK inhibitor) was added during in vitro differentiation of adipose stem cells derived from WT and ICAM-1- / - mice to observe the adipogenic differentiation status of adipose stem cells by oil red staining, respectively. Figure 6D shows that the expression of Perilipin A protein after adipogenic differentiation of adipose stem cells derived from WT and ICAM-1- / - mice under Y-27623 or DMSO treatment was detected by Western blot. Figure 6E, Figure 6F show that the real-time PCR method was used to detect the mRNA levels of Pparg (Figure 6E) and Fabp4 (Figure 6F) after adipose stem cell adipogenic differentiation derived from WT and ICAM-1- / - mice under Y-27623 or DMSO treatment, respectively. Figure 6G shows that RA2 (Rho agonist) was added during in vitro differentiation of adipose stem cells derived from WT and ICAM-1- / - mice, and the adipogenic differentiation status was observed by Oil Red staining, respectively. Figure 6H-6K show that the real-time PCR method was used to detect the mRNA levels of Pparg (Figure 6H), Cebpa (Figure 6I), Fabp4 (Figure 6J) and Plin1 (Figure 6K), respectively. Figures 6L to 6N show that RA2 (0.5 μg, once every 2 days) was injected into the right subcutaneous adipose tissue of WT mice and ICAM-1- / - mice in which obesity was induced by a high-fat diet, and the results were visually observed (Figure 6L), adipose tissue was observed (Figure 6M), and the changes in subcutaneous adipose tissue weight were statistically analyzed (6N), respectively.

[0026] [Figure 7]The effect of ICAM-1 in the recognition and regulation of human adipose stem cells is shown. Figure 7A shows the expression of ICAM-1 in human adipose tissue preadipocytes by flow cytometry analysis technique. Figure 7B shows the tissue location of ICAM-1+ adipose stem cells in human adipose tissue detected by immunofluorescence method. Figure 7C shows the expression changes of ICAM-1 and FABP4 during the adipose stem cell adipogenic differentiation process detected by real time PCR method. Figure 7D shows the expression of ICAM-1 in human adipose stem cells was knocked down using ICAM-1 siRNA. Figure 7E shows the adipogenic differentiation ability of cells was observed by oil red staining after the expression of ICAM-1 in human adipose stem cells was knocked down using ICAM-1 siRNA. Figure 7F-7G respectively show the adipogenesis-related gene expression and Rho GTP activity of adipose stem cells were detected, which interfered with ICAM-1 expression in the adipogenic differentiation process. Figures 7H-7J show that after interfering with ICAM-1 expression, Rho was activated with RA2, and the expression of adipogenic differentiation-related genes (PPARG, CEBPA, FABP4) in adipose stem cells was observed. Figures 7K-7L show that human adipose tissue specimens were used to perform association analysis on body fat percentage BMI index, ICAM-1 expression intensity, and expression level of Fabp4+ adipose precursor cells in CD31-CD45- adipose stromal cells, respectively. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0027] Through extensive and thorough research, the present inventors have for the first time discovered a new molecule for recognizing adipose stem cells. Specifically, the present invention provides the application of ICAM-1 and its regulators in promoting or inhibiting differentiation of adipose stem cells into adipocytes, and the application of ICAM-1 or its detection reagents in (a) detecting adipose stem cells, and / or (b) assessing the risk of a subject developing obesity, and corresponding diagnostic kits and methods. The present invention further provides a method for non-therapeutic preparation of adipocytes in vitro. Experiments have shown that ICAM-1 +Adipose stem cells are located around blood vessels in adipose tissue and have the ability to spontaneously differentiate into adipocytes in vitro and in vivo, and can participate in the development and remodeling of adipose tissue. + The number of adipose stem cells is proportional to the increase in obese adipose hypertrophy and hyperplasia, and can be used as a guide for diagnosing obesity. Based on this, the present invention was completed.

[0028] term As used herein, the term "targeted preadipocytes", "preadipocytes" refers to mesenchymal stem cells that begin to lose the pluripotency of adipose tissue and become progenitor cells capable of differentiating into adipocytes. The term "stromal reserve cells" as used herein refers to cells in the adipose stromal tissue whose differentiation characteristics are unknown and which may have certain adipogenic differentiation potential, but less than that of preadipocytes. The term "adipose stromal cells" as used herein refers to cells of adipose tissue that are non-blood and non-endothelial cells that have many of the characteristics of mesenchymal stem cells. As used herein, the term "adipose stem cells" refers to stem cells that can differentiate into adipocytes.

[0029] ICAM-1 Intercellular adhesion molecule-1 (ICAM-1, CD54) is a cell surface adhesion molecule that has attracted attention. It is a type I transmembrane protein with a molecular weight ranging from 80 kDa to 114 kDa depending on the degree of glycosylation, with nonglycosylated ICAM-1 having a molecular weight of 60 kDa (38). The extracellular portion of ICAM-1 contains 453 amino acids, mostly hydrophobic amino acids, forming five immunoglobulin (Ig)-like domains. The extracellular portion is connected to a very short (containing 28 amino acids) cytoplasmic tail via a hydrophobic transmembrane region containing 24 amino acids. The cytoplasmic tail lacks a typical signaling motif, but has a tyrosine residue that may play an important role in its signal transduction. The gene sequence of ICAM-1 contains seven exons, exon 1 encodes a signal peptide, exons 2–6 encode one of the five Ig domains, and exon 7 encodes the transmembrane region and the cytoplasmic tail. Ligands for ICAM-1 include the β2 integrin LFA-1 (CD11a / CD18) and Mac-1 (CD11b / CD18) on leukocytes, fibrinogen, and rhinoviruses.

[0030] ICAM-1 plays an important role in both innate and adaptive immune responses. It mediates leukocytes through the vascular wall to enter the inflammatory site, and also regulates the interaction between antigen presenting cells (APCs) and T cells, participating in the formation of immunological synapse. ICAM-1 can transmit signals from outside to inside. The tail of the cytoplasmic region of ICAM-1 has only 28 amino acids in length and lacks known kinase activity and protein interaction domains that can recruit downstream signaling molecules. However, it has many positively charged amino acids and one tyrosine residue (Y512). At present, many signaling molecules and linker proteins from different cells have been found to be associated with the ICAM-1 pathway, especially actin-cytoskeleton-associated molecules including α-actinin, ERM proteins, cortactin, and β-tubulin. In B cells, ICAM-1 cross-linking can activate Src family kinases such as p53 / p56 Lyn. A crucial molecule in the ICAM-1 signaling pathway is the small GTPase Rho, a member of the Ras superfamily of G proteins; Rho and downstream Rho associated kinase (ROCK) regulate cytoskeletal reorganization and play a key role in maintaining cell morphology. Antibody cross-linking or co-culture with monocytes induces ICAM-1 clustering, as well as colocalization of ERM proteins and stress fiber assembly. This process requires activation of RhoA, and the cytoplasmic tail of ICAM-1 plays a key role in this process: ICAM-1 clusters lacking the cytoplasmic tail cannot activate Rho proteins. Rho activation and inactivation are tightly regulated by many factors, including guanine exchange factors (GEFs), GTPase activating proteins (GAPs), and guanine nucleotide dissociation inhibitors (GDIs).The specific mechanism by which ICAM-1 activates Rho is unclear, but ERM proteins and Rho-GDI may play important roles. On endothelial cells, ICAM-1 binds to LFA-1 or Mac-1 on leukocytes and activates downstream Rho and ROCK, leading to cytoskeletal rearrangements and morphological changes that mediate leukocyte translocation through blood vessels and entry into inflamed tissues. The ICAMI-1 positive adipose stromal cells obtained by sorting can be used for medical aesthetics such as adipose tissue remodeling.

[0031] ICAM-1 inhibitors and enhancers The present invention provides the use of an ICAM-1 inhibitor in inhibiting differentiation of adipose stem cells into adipocytes, and the use of ICAM-1 or a promoter thereof in promoting differentiation of adipose stem cells into adipocytes, wherein the ICAM-1 inhibitor specifically inhibits the expression or activity of ICAM-1, and the ICAM-1 promoter specifically promotes the expression or activity of ICAM-1. Based on the above application, the present invention further provides a method for non-therapeutic preparation of adipocytes in vitro, the method comprising: (a) providing ICAM-1 positive adipose stromal cells; (b) culturing the adipose stromal cells under conditions suitable for adipocyte differentiation to obtain a cell population comprising differentiated adipocytes; (c) isolating adipocytes from said cell population; Includes.

[0032] RNA interference (RNAi) In the present invention, an effective ICAM-1 inhibitor is an interfering RNA. The term "RNA interference (RNAi)" as used herein refers to some small double-stranded RNAs that can efficiently and specifically block the expression of specific genes in the body, promote the degradation of mRNA, and induce cells to show phenotypes of specific genes' defects, also called RNA intervention or RNA interference. RNA interference is a highly specific gene suppression mechanism at the mRNA level. As used herein, the term "small interfering RNA (siRNA)" refers to short double-stranded RNA molecules that can target homologous complementary sequences in mRNAs and degrade specific mRNAs; this process is the RNA interference pathway. In the present invention, interfering RNA includes siRNA, shRNA and corresponding constructs.

[0033] Typical constructs are double stranded, the plus or minus strand of which contains the structure shown in Formula I. Seq 順方向 -X-Seq 逆方向 Formula I During the ceremony, Seq 順方向 is the nucleotide sequence of the ICAM-1 gene or fragment, Seq 逆方向 Seq 順方向 is a nucleotide sequence essentially complementary to X is Seq 順方向 and Seq 逆方向 and the spacer sequence is located between Seq 順方向 and Seq 逆方向 is not complementary to In one preferred embodiment of the present invention, Seq 順方向 , Seq 逆方向 The length is 19 to 30 bp, preferably 20 to 25 bp.

[0034] In the present invention, an exemplary shRNA is as shown in Formula II: [ka] During the ceremony, Seq' 順方向 Seq 順方向 an RNA sequence or sequence fragment corresponding to the sequence, Seq' 逆方向 Seq' 順方向 is essentially a complementary sequence to X' is None or Seq' 順方向 and Seq' 逆方向 and the spacer sequence is located between Seq' 順方向 and Seq' 逆方向 is not complementary to [ka] Seq 順方向 and Seq 逆方向 This represents the hydrogen bond formed between In another preferred example, the length of the spacer sequence X is 3 to 30 bp, preferably 4 to 20 bp. Here, Seq 順方向 Target genes targeted by the sequence include, but are not limited to, Beclin-1, LC3B, ATG5, ATG12, or combinations thereof.

[0035] Compositions and Methods of Administration The present invention further provides a composition for promoting or inhibiting differentiation of adipose stem cells into adipocytes, comprising an ICAM-1 inhibitor or promoter as an active ingredient, including, but not limited to, a pharmaceutical composition, a food composition, a dietary supplement, a beverage composition, and the like. In the present invention, the ICAM-1 inhibitor can be directly used for medical aesthetics, such as remodeling of fat cells. When using the ICAM-1 inhibitor of the present invention, other components can be used at the same time, such as in combination with fat stem cells.

[0036] The present invention further provides a pharmaceutical composition comprising a safe and effective amount of the ICAM-1 inhibitor or promoter of the present invention and a pharma- ceutical acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffer, glucose, water, glycerin, ethanol, powder, and combinations thereof. The pharmaceutical needs to be matched with the method of administration. The pharmaceutical composition of the present invention can be prepared in the form of an injection, for example, by using saline or an aqueous solution containing glucose and other adjuvants, and can be prepared by conventional methods. Pharmaceutical compositions such as tablets and capsules can be prepared by conventional methods. Pharmaceutical compositions such as injections, liquids, tablets, capsules, etc. need to be manufactured under sterile conditions. The pharmaceutical composition of the present invention can also be made into a powder for aerosol inhalation. The amount of the active ingredient administered is a therapeutically effective amount, for example, about 1 μg / kg body weight to about 5 mg / kg body weight / day. The ICAM-1 inhibitor of the present invention can be used in combination with other therapeutic agents.

[0037] The pharmaceutical composition of the present invention can be administered to a desired subject (such as a human or non-human mammal) by a conventional method. Representative administration methods include, but are not limited to, oral administration, injection, aerosol inhalation, etc. When using pharmaceutical compositions, a safe and effective amount of the ICAM-1 inhibitor is administered to the mammal, which safe and effective amount will usually be at least about 10 μg / kg body weight, and in most cases will not exceed about 8 mg / kg body weight, and preferably will be from about 10 μg / kg body weight to about 1 mg / kg body weight. Of course, the particular dosage will also take into account factors such as the route of administration, the health condition of the patient, etc., which are within the skill of the skilled physician.

[0038] Detection Reagents The detection reagent of the present invention includes a protein chip, a nucleic acid chip, or a combination thereof. In another preferred embodiment, the detection reagent of the present invention further comprises an ICAM-1 specific antibody. Protein chips are high-throughput monitoring systems that monitor interactions between protein molecules through the interaction of target molecules and capture molecules. Capture molecules are generally immobilized on the chip surface, and are widely used as capture molecules due to their high antibody specificity and strong antigen binding. In protein chip research, it is very important to effectively immobilize antibodies on the chip surface, and it is very important, especially in the consistency of immobilized antibodies, to increase the sensitivity of protein chips. G protein is an antibody-binding protein that specifically binds to antibody FC fragments, and is therefore widely used to immobilize various types of antibodies. The protein chip for detecting ICAM-1 of the present invention can be prepared by various techniques known to those skilled in the art.

[0039] Nucleic acid chips, also known as DNA chips, gene chips, and microarrays, are made by synthesizing oligonucleotides in situ on a solid support or by directly immobilizing a large number of DNA probes on the surface of the support in sequence by microprinting, hybridizing them with a labeled sample, and detecting and analyzing the hybridization signal to obtain the genetic information of the sample. In other words, gene chips are made by microprocessing technology to process tens of thousands or millions of DNA fragments (gene probes) on a 2cm 2 These are arranged on a support such as a silicon wafer or slide to form a two-dimensional DNA probe array, which resembles the electronic chips in electronic computers and is therefore called a gene chip. The present invention relates to polyclonal and monoclonal antibodies, particularly monoclonal antibodies, specific for human ICAM-1. Here, "specific" means that the antibody can bind to human ICAM-1 gene products or fragments. Preferably, it refers to those antibodies that can bind to human ICAM-1 gene products or fragments, but do not recognize and bind other unrelated antigen molecules. Antibodies in the present invention include molecules that can bind and inhibit human ICAM-1 protein, as well as those that do not affect the function of human ICAM-1 protein. The present invention further includes antibodies that can bind to modified or unmodified forms of human ICAM-1 gene products.

[0040] The present invention further includes not only complete monoclonal or polyclonal antibodies, but also immunologically active antibody fragments such as Fab' or (Fab)2 fragments, antibody heavy chains, antibody light chains, genetically engineered single chain Fv molecules (Ladner et al., U.S. Pat. No. 4,946,778), or chimeric antibodies, such as antibodies having the binding specificity of a murine antibody but still retaining portions of the antibody from human origin.

[0041] The antibodies of the present invention can be prepared by various techniques known to those skilled in the art. For example, a purified human ICAM-1 gene product or an antigenic fragment thereof can be administered to an animal to induce the production of polyclonal antibodies. Similarly, cells expressing the human ICAM-1 protein or an antigenic fragment can be used to immunize an animal to produce antibodies. The antibodies of the present invention may be monoclonal antibodies. Such monoclonal antibodies can be prepared using hybridoma technology (Kohler et al., Nature 256;495, 1975;Kohler et al. Eur. J. Immunol. 6:511, 1976; Kohler et al. Eur. J. Immunol. 6:292, 1976;Hammerling et al. In Monoclonal Antibodies and T Cell Hybridomas, Elsevier, NY, 1981). The antibodies of the invention include antibodies capable of blocking the function of the human ICAM-1 protein and antibodies that do not affect the function of the human ICAM-1 protein. The various antibodies of the invention can be obtained by conventional immunization techniques using fragments or functional regions of the human ICAM-1 gene product. These fragments or functional regions can be prepared by recombinant methods or synthesized using a polypeptide synthesizer. Antibodies that bind to unmodified forms of the human ICAM-1 gene product can be generated by immunizing animals with the gene product produced in prokaryotic cells (such as E. coli), and post-translationally modified forms (such as glycosylated or phosphorylated proteins or peptides) can be obtained by immunizing animals with the gene product produced in eukaryotic cells (such as yeast or insect cells).

[0042] Detection method and detection kit The present invention provides a detection method and a detection kit using ICAM-1 and a detection reagent thereof. Specifically, the present invention provides such a kit comprising a container containing ICAM-1 or a detection reagent thereof, and a label or instructions clearly indicating that the kit is used for (a) detecting adipose stem cells and / or (b) determining a subject's risk of developing obesity.

[0043] The present invention further provides a method for determining a risk of developing obesity in a subject, the method comprising: (a) providing a sample of subjects; A1 is ICAM-1 of the above sample + (b) measuring the proportion of cells; (b) ICAM-1 in normal population samples + (c) comparing the proportion of cells A0 and explaining that if A1 is significantly higher than A0, the subject is at high risk of developing obesity; Includes. In another preferred embodiment, the method further comprises: + The cell ratio B1 was measured, and B1 was compared with the normal population of FABP4+ The method further includes comparing the cell ratio B0 to the cell ratio B1 and describing the subject as being at increased risk for developing obesity if B1 is significantly lower than B0.

[0044] The present invention includes the following main advantages: (a) The present invention relates to ICAM-1 + We have found that adipose stem cells have the ability to spontaneously differentiate into adipogenic cells, can differentiate into adipocytes in in vitro and in vivo experiments, and can participate in the development and remodeling of adipose tissue. (b) The present invention relates to ICAM-1 + We found that the number of adipose stem cells is proportional to the increase in obese adipose hypertrophy and hyperplasia and can be used as a guide for diagnosing obesity. (c) The present invention discovered that ICAM-1 has a negative regulatory effect on the in vivo adipogenic differentiation of human preadipocytes, and that the expression level of ICAM1 in human preadipocytes gradually decreases along with adipogenic differentiation.

[0045] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and do not limit the scope of the present invention. Experimental methods without specific conditions in the following examples are usually based on conventional conditions or conditions recommended by manufacturers. Unless otherwise specified, percentages and parts are calculated by weight.

[0046] General Materials and Methods ICAM-1 - / -Mice (B6.129S4-Icam1tm1Jcgr / J) were purchased from Jackson Laboratory (Bar Harbor, ME, USA). Fabp4-Cre (B6.Cg-Tg(Fabp4-cre)1Rev / JNju) mice, mTmG (B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo / JNju) mice were purchased from Nanjing Model Animal Institute. Icam1-CreERT2 knock-in mice were constructed by Nanfang Model Biology Center, and the CreERT2 expression sequence was directly inserted into the start codon ATG of the Icam1 gene using Cas9 technology.

[0047] Tamoxifen induces lineage tracing in vivo After birth, Icam-1-CreRET2, mTmG mice were injected intraperitoneally with 200 μg / mice Tamoxifen for three consecutive days from P1 to P3. Tamoxifen was formulated in corn oil as a mother solution at 20 mg / ml. After 4–6 weeks, mice were euthanized and adipose tissue was analyzed for EGFP expression. + Adipocytes were detected.

[0048] Detection of mouse body fat percentage A body composition analyzer was used to detect adipose tissue and other "lean" tissue in the high-fat-induced obese mice, and each mouse was measured two to three times in succession, with the average values ​​obtained.

[0049] Cultivation of adipose stromal cells Sorted CD31 - CD45 - Sca-1 + PDGFR-α + Adipose stromal cells, CD31 - CD45 - Sca-1 + PDGFR-α + ICAM-1 + and CD31 - CD45 - Sca-1 + PDGFR-α +ICAM-1 - These components were cultured alone or in mixtures in DMEM low glucose medium supplemented with 10% FBS. In some experiments, adherent adipose mononuclear cells were directly cultured in DMEM low glucose medium supplemented with 10% FBS, and immune cells and vascular endothelial cells were removed by liquid exchange and passaging to obtain pure adipose stromal cells.

[0050] Induction of stromal cell adipogenic differentiation Differentiation medium was prepared by adding 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 50 μM indomethacin, 10 μg / ml insulin and 0.5 μM dexamethasone to DMEM high glucose medium with 10% FBS. When the adipose stromal cells grew to 100% confluence, the differentiation medium was changed and the medium was changed about every 2 days until differentiation was completed, which took about 5 days.

[0051] [Example 1] ICAM-1-expressing adipose stromal cells are potential adipose stem cells Non-endothelial and non-leukocyte (CD31) expression in adipose tissue rich in adipose stem cells - CD45 - By analyzing the cellular characteristics of CD31 - CD45 - Most of the interstitial cells are CD34 + and CD29 + and at the same time, PDGFR-α + Sca-1 + (Figure 1A), the latter being two characteristic surface molecules of mesenchymal stromal cells (MSCs). Further analysis of adipose stromal cells by flow cytometry revealed that CD45 - CD31 - Most of the interstitial cells are Sca-1 + PDGFR-α + and this cell population expresses ICAM-1 + and ICAM-1 -These populations can be divided into two groups: CD45 - CD31 - Sca-1 + PDGFR-α + We found that approximately 50% of the cells in inguinal adipose tissue (subcutaneous adipose tissue) and approximately 80% of the cells in epididymal adipose tissue (visceral adipose tissue) were ICAM-1 positive (Figure 1B).

[0052] Flow cytometric sorting identified two groups of stromal cells: CD45 - CD31 - Sca-1 + PDGFR-α + ICAM-1 + and CD45 - CD31 - Sca-1 + PDGFR-α + ICAM-1 - We obtained and genetically analyzed the adipocyte precursor cells, and the analysis revealed that the adipocyte precursor cells characteristic molecules Pdgfrb, Zfp423, and the adipogenic differentiation-related molecules Pparg, Cebpa, and Fabp4 were expressed on ICAM-1. + The results showed that preadipocytes were mainly present in ICAM-1 positive stromal cells, whereas ICAM-1 + Adipose stromal cells (CD31 - CD45 - Sca-1 + PDGFR-α + ) have been shown to be enriched in adipose stem cells and preadipocytes.

[0053] ICAM-1 + To further test whether adipose stem cells have the potential for spontaneous adipogenesis, we used ICAM-1 + Adipose stromal cells (CD31 - CD45 - Sca-1 + PDGFR-α + ) and ICAM-1 - Adipose stromal cells (CD31 - CD45 - Sca-1 + PDGFR-α+ ) were sorted and analyzed for their ability to undergo spontaneous adipogenic differentiation. Considering that spontaneous adipogenic differentiation may be the result of mutual influence of different cell populations through paracrine or other effects, we selected wild-type ICAM-1 - Interstitial cells express ICAM-1 in EGFP mice + Stromal cells are cultured in a mixed fashion, allowing the tracking of different cell populations without affecting their interactions. The results showed that during the initial adherent growth period, cells derived from both types exhibited fibroblast morphology, and at the later stage of culture (day 8), spontaneous adipogenic differentiation occurred, with some cells accumulating lipid droplets, and most of the spontaneous adipogenic differentiated cells expressed EGFP. + and ICAM-1 + These results suggest that adipose stromal cells may be adipose stem cells (Figure 1D).

[0054] At the same time, reverse mixed culture was performed -- wild-type ICAM-1 + ICAM-1 on cells and EGFP - The cells were mixed and cultured, and all cells that spontaneously differentiated into adipogenic cells expressed ICAM-1 + ICAM-1 - Adipose stromal cells and ICAM-1 + Adipose stromal cells were cultured separately and expressed ICAM-1 + These results suggest that only ICAM-1 cells can spontaneously differentiate into adipocytes. + This indicates that adipose stromal cells are adipose stem cells with the ability to differentiate into adipogenic cells.

[0055] [Example 2] ICAM-1 + In vivo adipogenic differentiation of adipose stem cells ICAM-1 +To fully verify whether adipose stromal cells are adipose stem cells, i.e., whether they can generate mature adipocytes in vivo, we created Icam1-CreERT2 knock-in mice and knocked in the CreERT2 expression box at the ATG site of the ICAM-1 gene by homologous recombination using CRISPR / Cas9 technology. In these Icam1-CreERT2 knock-in mice, all cells expressing ICAM-1 express CreERT2, and CreERT2 itself has no recombinase activity and needs to be combined with tamoxifen to activate recombinase activity. In the mTmG tracer reporter mice, in the absence of Cre recombinase, cells and tissues throughout the body express a red fluorescent protein --tdTomato, which is located on the cell membrane, and in the presence of Cre recombinase, the tdTomato expression sequence is deleted by recombination, downstream cell membrane-localized EGFP expression is initiated, and its progeny cells express only cell membrane-localized EGFP. Therefore, we crossed the Icam1-CreERT2 knock-in mice with the tracer reporter mice mTmG and treated the newborn mice with tamoxifen to activate the recombinase activity. + The activated CreERT2 recombinase of the cells cleaves the tdTomato expression sequence between the two loxP sites in the Rosa26 locus and initiates the expression of EGFP at the subsequent sequence, thus cleaving the ICAM-1 + The cells and all of their derived progeny cells express EGFP (Fig. 2A).

[0056] The results showed that after neonatal mice were treated with tamoxifen, EGFP adipocytes were detected in subcutaneous and visceral adipose tissues in adulthood (Figure 2B). More importantly, mice with obesity induced by a high-fat diet were treated with tamoxifen at an early stage, and EGFP adipocytes were also observed at a later stage of obesity (Figure 2C). Because adipocytes do not express ICAM-1, the above results suggest that EGFP adipocytes are involved in the expression of ICAM-1. + These results suggest that adipocytes are involved in adipose development and obesity processes through their differentiation into mature adipocytes.

[0057] In addition, CD45 expression in adipose tissue after hybridization of Icam1-CreERT2 knock-in mice and tracer-report mice (mTmG) was - CD31 - ICAM-1 + Cells and CD45 - CD31 - ICAM-1 - The cells were then isolated from Matrigel (basement membrane matrix), mixed and transplanted into the subcutaneous tissue of mice, and treated with tamoxifen to observe fat differentiation. + We showed that the cells could differentiate into adipocytes labeled with EGFP, which expressed ICAM-1 - The cells were hardly observed in the Matrigel in which they were embedded (Figure 2D). This is because the present invention is - CD31 - ICAM-1 + This paper explains how adipose stem cells (adipose stromal cells) can be implanted in the body and spontaneously differentiated into adipocytes.

[0058] [Example 3] ICAM-1 in obesity + Adipogenic differentiation of adipose stem cells Next, ICAM-1 + To investigate the correlation between preadipocytes and obesity, we introduced another lineage tracing system. FABP4 is a characteristic molecule expressed when adipose stem cells transform into adipocytes. By hybridizing Fabp4-Cre mice with mTmG tracer mice, the adipogenic differentiation of preadipocytes progresses to the early adipocyte stage of Fabp4 expression in the resulting progeny mice, which express EGFP (Figure 3A). Fabp4-Cre, mTmG mice were fed a normal diet and a high-fat diet, respectively, and the interstitial cells (CD45 - CD31 - Sca-1 + ) in EGFP + We analyzed early differentiated adipocytes expressing

[0059] In this study, under typical diet-fed conditions, Fabp4-Cre, mTmG adult mice expressed small amounts of EGFP in the adipose tissue of Fabp4-Cre mice from the same litter. + Only adipose precursor cells, mainly CD31 - CD45 - Sca-1 + ICAM-1 + (Figure 3B), which is ICAM-1. + Derived from adipose stem cells, maintains the surface molecular phenotype of adipose stem cells, and expresses ICAM-1 + We show that adipose stem cells are involved in the normal replacement of adipocytes. Importantly, when these mice were induced to become obese with a high-fat diet, there were numerous early adipocytes expressing EGFP and expressing ICAM-1 in both adipose tissues. + Surface molecular characteristics of adipose stem cells (CD31 - CD45 - Sca-1 + ICAM-1 + ) (Figure 3C–D), indicating that obesity induces adipocyte regeneration, and these newly differentiated adipocytes mainly express ICAM-1 + We demonstrate that these EGFP-dependent markers originate from adipose stem cells. + ICAM-1 + They found that early adipocytes were all located around blood vessels and expressed ICAM-1 + It is located in the same location as adipose stem cells (Figure 3E).

[0060] These ICAM-1 + EGFP + To further identify the cells, mature adipocytes, ICAM-1 + EGFP + , ICAM-1 + EGFP - and ICAM-1 - Cell subsets were sorted from obese mice for RNA-seq analysis. ICAM-1 + EGFP + The gene expression profile of the subset was ICAM-1 + EGFP -The correlation coefficient is 0.98 (Figure 3F). + EGFP + The cells have a similar gene expression pattern to adipocytes (Figure 3F), especially when focusing on genes characteristic of adipocyte signaling pathways (Figure 3G). In expression of these adipocyte-characteristic genes, adipocytes express ICAM-1 + EGFP + and ICAM-1. + EGFP - The cells then express ICAM-1 - These results suggest that ICAM-1 has the lowest correlation with + EGFP + Cells express ICAM-1 + EGFP - This indicates that they are intermediate products of adipogenic differentiation derived from adipose stem cells.

[0061] [Example 4] ICAM-1 negatively regulates terminal differentiation of preadipocytes Based on the above studies, it was proven that ICAM-1 is expressed in adipose stem cells and preadipocytes, which undergo adipogenic differentiation when obesity occurs, but mature adipocytes do not express ICAM-1, and ICAM-1 expression gradually decreased with adipogenic differentiation. This expression profile is very similar to the preadipocyte characteristic genes Pref-1 and GATA2 / GATA3, which have the function of resisting adipogenic differentiation and maintaining the undifferentiated state of preadipocytes. Based on this, it can be speculated that ICAM-1 exerts the same regulatory effect. In this study, compared with wild-type mice, ICAM-1 - / - We found that mice significantly increased their body weight and adipose tissue weight under normal or high-fat diet conditions, and the increase in adipose tissue was not dependent on an increase in the amount of adipocytes (Figure 4A-D). Because ICAM-1 is expressed on immune cells, to exclude the effect of ICAM-1 deletion on obesity, we performed bone marrow replacement experiments and examined whether ICAM-1 expression was related to the effect of ICAM-1 deletion on obesity. - / -We found that even when the immune cells of mice were replaced with those of wild-type mice, they were still prone to obesity (Figure 4E-F). Because adipose hyperplasia involves two modes of cell expansion and increase, ICAM-1 - / - We found that the size of adipocytes in mice was not significantly increased (Figure 4G-H), indicating that an increase in the number of adipocytes plays a role in obesity, which is a result of excessive differentiation of adipose stem cells.

[0062] To determine the contribution of increased adipocyte numbers to the development of obesity, ICAM-1 - / - Mice were crossed with Fabp4-Cre, mTmG mice, and ICAM-1 + / + , Fabp4-Cre, mTmG compared with littermates, ICAM-1 - / - , Fabp4-Cre, mTmG mice with EGFP + The number of cells in the adipocyte differentiation intermediate state was significantly increased (Figure 4I-K), indicating that deletion of ICAM-1 can promote the adipogenic differentiation process of adipose stem cells in vivo. Compared to wild-type adipose stem cells, ICAM-1 - / - Primary preadipocytes differentiated faster (Figure 4H), and adipogenic differentiation genes (including Pparg, Cebpa, Fabp4, and Plin1) were significantly increased (Figure 5A-D). Thus, ICAM-1 negatively regulates the terminal differentiation of adipose stem cells.

[0063] [Example 5] ICAM-1 maintains the undifferentiated state of adipose stem cells via Rho and ROCK Next, we will deeply discuss the molecular mechanism of ICAM-1 regulating adipogenic differentiation. A very important component of the downstream signal of ICAM-1 is the small GTPase Rho. ICAM-1 - / -We found that preadipocytes had significantly less activated Rho (Rho-GTP) and higher inactivated Rho-GDP than wild-type progenitor cells (Figure 6A). Activated Rho can regulate the formation of intracellular stress fibers through ROCK. Through F-actin fluorescent immunoassay, we found that wild-type progenitor cells had numerous tightly structured stress fibers, coexisting with F-actin bundles and ICAM-1 clusters, and ICAM-1 was expressed in the wild-type progenitor cells. - / - We found that in adipose precursor cells, the density of stress fibers was significantly lower than that in wild-type stromal cells, the structure was loose, and there were few fiber bundles (Figure 6B), indicating that ICAM-1 activates Rho and ROCK in adipose precursor cells and plays an important role in the organization of stress fibers and the organization of the cytoskeleton.

[0064] Rho and ROCK can negatively regulate adipogenic differentiation in a cytoskeleton-dependent or insulin signal-dependent manner, and at the same time, RNA-seq data also support the role of Rho GTPase in adipogenic differentiation. To test whether Rho and ROCK are involved in the inhibitory effect of ICAM-1 on adipogenic differentiation of adipose stem cells, we treated adipose stem cells with ROCK inhibitor Y-27632, respectively. Compared with the DMSO-treated group, we found that Y-27623 could significantly accelerate the adipogenic differentiation of wild-type adipose stem cells, but not ICAM-1. - / - The effect on adipogenic differentiation of adipose stem cells is unclear (Figure 6C). At the same time, we analyzed the expression level of Perilipin A, a characteristic protein of mature adipocytes, and found that Y-27632 could significantly increase the expression level of this protein in wild-type adipose stem cells, but not ICAM-1. - / - There was no significant effect on adipose stem cells (Figure 6C). Also, inhibition of ROCK could significantly increase the expression of adipogenic differentiation-related proteins and genes in wild-type mouse adipose stem cells, including perilipin A, Pparg and Fabp4, but not ICAM-1. - / - ICAM-1 inhibits adipogenic differentiation of adipose stem cells via the Rho-ROCK pathway, as its effect in mouse-derived adipose stem cells is unclear (Figure 6D-F).

[0065] To test whether Rho GTPase activity could reverse the excessive adipogenic differentiation caused by ICAM-1 deletion, we used the Rho agonist Rho activator II (RA2), which can constitutively activate Rho GTPase. - / - We found that ICAM-1 significantly inhibited the adipogenic differentiation ability of adipose stem cells, but had no obvious effect on wild-type adipocytes (Figure 6G). - / - Activation of Rho GTPases in progenitor cells led to a widespread reduction in adipogenic differentiation genes, including Pparg, Cebpa, Fabp4, and Plin1, whereas only Pparg and Fabp4 were significantly altered by Rho GTPase activation in wild-type cells (Figure 6H–K). Importantly, both wild-type and ICAM-1 - / - The difference in expression of adipogenic differentiation genes in the cells was eliminated by activation of Rho GTPase (Figure 6H-K). These results confirmed that ICAM-1 regulates adipogenic differentiation via Rho GTPase.

[0066] To test whether ICAM-1 regulates Rho GTPase-induced adipogenesis in vivo, we locally injected RA2 into the right inguinal fat pad of mice and demonstrated the effect of local activation of Rho GTPase compared with the left fat pad. After 10 weeks of RA treatment in mice fed a high-fat diet, ICAM-1 - / - The mice showed asymmetry in the inguinal fat pads on both sides of the face (Figure 6L). This asymmetry was not observed in RA2-treated WT mice and PBS-treated mice (Figure 6L). When these adipose tissues were collected and weighed, we found that RA2, but not WT mice, upregulated ICAM-1 - / - It was found that it significantly reduced fat weight (Figure 6M-N).

[0067] [Example 6] ICAM-1 negatively regulates human preadipocyte differentiation First, we analyzed the expression level of ICAM-1 in human adipose tissue. Currently, there is no known molecule characteristic of human adipose precursor cells. ICAM-1 is a marker of human CD31 - CD45 - We found that ICAM-1 is widely expressed in adipose stromal cells (Fig. 7A). + The cells are mainly located around blood vessels (Figure 7B), similar to mouse adipose tissue. To test the regulatory effect of ICAM-1 on human adipose stem cells, we isolated human primary adipose stem cells and induced adipogenic differentiation. Consistent with mice, we found that the expression level of ICAM1 in human preadipocytes gradually decreased with adipogenic differentiation (Figure 7C). When we knocked down the expression of ICAM1 with siRNA (Figure 7D), the adipogenic differentiation of human preadipocytes was significantly enhanced (Figure 7E), and the expression of adipogenic genes, including PPARG, CEBPA and FABP4, was significantly increased (Figure 7F), indicating that ICAM-1 has a negative regulatory effect on the adipogenic differentiation of human adipose stem cells. It should be noted that knockdown of ICAM-1 reduced the Rho GTPase activity of human adipose stem cells (Figure 7G). Treating human adipose stem cells with RA2 during differentiation eliminated the enhanced adipogenic differentiation of ICAM-1 knockdown cells (Figure 7H-J). Thus, ICAM-1 also has the ability to negatively regulate the terminal differentiation of human adipose stem cells.

[0068] To test the physiological effects of ICAM-1 on human preadipocytes, we collected samples of human adipose tissue from patients undergoing plastic surgery and used flow cytometry to detect the expression of CD31 - CD45 - The expression levels of ICAM-1 and FABP4 in adipose stromal cells were analyzed. The expression level of ICAM-1 was significantly correlated with the body fat percentage (BMI) of the subjects (Figure 7K), a result similar to that observed in mice. Linear regression analysis was used to determine the correlation between the expression level of ICAM-1 and FABP4 + We tested the correlation with the proportion of preadipocytes. Considering the strong correlation between BMI and ICAM-1 expression, we introduced a linear model in which the interaction term between BMI and ICAM-1 MFI was modified. Based on this, FABP4+ We found that the proportion of preadipocytes was significantly negatively correlated with the expression level of ICAM-1 ( Figures 7K–L ), indicating that ICAM-1 has a negative regulatory role in the adipogenic differentiation of human preadipocytes in vivo .

[0069] All documents mentioned in this application are incorporated by reference into this application as if each document was individually incorporated by reference. Furthermore, after reading the above teachings of the present invention, those skilled in the art will be able to make various changes or modifications to the present invention, and these equivalents are also within the scope defined by the claims appended hereto.

Claims

1. Use of an inhibitor that inhibits the expression of ICAM-1, It is used to prepare a preparation or composition that promotes spontaneous differentiation of adipose stem cells into adipocytes, The adipose stem cells are isolated from stromal cells separated from adipose tissue and express CD45 - CD31 - Sca-1 + PDGFR-α + ICAM-1 + Use of an inhibitor that inhibits the expression of ICAM-1, characterized in that the inhibitor is a cell.

2. The use of claim 1, characterized in that the adipose stem cells express regulatory genes for adipogenic differentiation, the regulatory genes being selected from Pparg, Cebpa, Cebpb, Cebpg, Gata2, Gata3, Irs1, Pparg, Cebpa, and Fabp4, or combinations thereof.

3. The use according to claim 1, characterized in that the preparation or composition is further used for remodeling adipose tissue.

4. 1. A method for non-therapeutic preparation of adipocytes in vitro, comprising: (a) providing ICAM-1 positive adipose stromal cells; (b) culturing the adipose stromal cells to spontaneously differentiate into adipocytes, and obtaining a cell population containing differentiated adipocytes; (c) isolating adipocytes from said cell population; Including, The adipose stromal cells are isolated from stromal cells separated from adipose tissue. - CD31 - Sca-1 + PDGFR-α + ICAM-1 + The in vitro method for non-therapeutic preparation of adipocytes, characterized in that the adipocytes are cells.

5. The method according to claim 4, characterized in that in steps (b) and (c), the expression level of ICAM-1 is detected to determine the degree of differentiation of adipose stromal cells into adipocytes in the cell population.

6. Use of a detection reagent for ICAM-1, (a) for detecting adipose stem cells; and (b) for preparing a detection kit for determining a subject's risk of developing obesity, The adipose stem cells express CD45 - CD31 - Sca-1 + PDGFR-α + ICAM-1 + The use of the ICAM-1 detection reagent, characterized in that the ICAM-1 + cell ratio A1 of a sample from a subject is compared with the corresponding ICAM-1 + cell ratio A0 of a normal population, and if A1 / A0 is ≧1.25, this indicates that the subject is at high risk of developing obesity.

7. A diagnostic kit comprising: A container containing an ICAM-1 detection reagent; (a) contain a label or instructions specifying that the product is used for detecting adipose stem cells, and (b) to determine a subject's risk for developing obesity; The adipose stem cells express CD45 - CD31 - Sca-1 + PDGFR-α + ICAM-1 + and the judgment is characterized in that the ICAM-1 + cell ratio A1 of a sample from a subject is compared with the corresponding ICAM-1 + cell ratio A0 of a normal population, and if A1 / A0 is ≧1.25, this indicates that the subject is at high risk of developing obesity.

8. Use of stromal cells, The stromal cells are isolated from adipose tissue and are ICAM-1 positive stromal cells, and the stromal cells are used to prepare a cell preparation for remodeling adipose tissue; The stromal cells express CD45 - CD31 - Sca-1 + PDGFR-α + ICAM-1 + The use of said stromal cells, characterized in that said stromal cells are cells.

Citation Information

Patent Citations

  • Method for restraining mesenchymal stem cells from differentiating into fat cells

    CN103103213A

  • Analysis of LPA4 receptor knockout animal

    JP2012239450A